no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
Systematic reviews (required regulatory step) take years manually. Sematic uses AI to automate literature screening, data extraction, and synthesis, reducing to hours. Product live with thousands of users across big pharma, academia, biotech. Raising pre-seed. Addresses core bottleneck in 9-10 year drug development timeline.
Daxib (daraxonrasib) uses molecular glue to drug KRAS G12C, previously considered undruggable. Phase 2 shows median overall survival doubled vs chemo (13 vs 7 months) with fewer adverse events. Tango Therapeutics combo further improves survival. First meaningful advance in decades for metastatic pancreatic cancer (3% 5-year survival).
Unlike tech, pharma faces patent cliffs where generics erode 95% of revenue after ~20 years. Tirzepatide doing $51B sales but will decline. Manufacturing scale for $50B drugs creates moat but also capex burden. 100T biotech valuation unlikely without patent reform or new modalities.